Home / Stock ratings / EDIT

Stock rating · Biological Products, (No Diagnostic Substances)

Editas Medicine, Inc. (EDIT) Stock Rating & Analysis

As of November 20, 2026, MELANY rates Editas Medicine, Inc. 46 out of 100 (Promising). Its highest factor score is earnings track record at 100, and its lowest is price momentum at 10.

MELANY ratingRated 2026-11-20

EDIT · composite score

46/100
Promising
Nov 20
Rating date
Live price in the app →
Quality26
Momentum10
Risk-adjusted25
Source basis SEC filings and live market dataDated snapshot

About Editas Medicine, Inc.

Editas Medicine Inc is a clinical-stage genome editing company developing genomic medicines for a broad range of serious diseases. Its proprietary gene editing platform is based on CRISPR technology, which uses a protein-RNA complex with an enzyme such as Cas9 (CRISPR-associated protein 9) or Cas12a (also known as Cpf1).

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why EDIT scores 46/100

EDIT's 8 factor scores run from 10 to 100, and 4 of them sit above its composite of 46. Here is how EDIT breaks down.

Valuation63/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

Business quality26/100

Margins, returns on capital, and balance-sheet strength.

Price momentum10/100

Direction and relative strength of the recent share-price trend.

Earnings track record100/100

History of beating or missing estimates, and where estimates are heading.

  • Beat EPS estimates 4 of last 4 quarters
  • Avg EPS beat +37%
Analyst sentiment89/100

What Wall Street price targets and revisions are signalling.

  • Analyst targets 272% upside
  • Institutional net buying +13.9%
Catalyst setup36/100

Near-term events that could move the stock.

Risk-adjusted profile25/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How EDIT compares

As of November 20, 2026, Editas Medicine, Inc. ranks 8th of the 10 companies with a MELANY rating page in its SEC industry group (Biological Products, (No Diagnostic Substances)), where the average score is 53.

All stock rating pages.

Key risks for EDIT

  • Operating margin -152%, cash-burn business, dependent on capital markets
  • Negative free cash flow, company consuming cash, not generating it
  • Short interest 25% of float, high volatility risk on news
  • Weak price momentum, trend not yet confirmed, may need more time to set up
  • High beta 2.1, amplifies market drawdowns 1.8x+ in selloffs

Sector and theme context

Editas Medicine, Inc. sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds EDIT's momentum and catalyst factors above.

EDIT trade plan (Pro)

MELANY has a full position plan for Editas Medicine, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates EDIT

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Editas Medicine, Inc.'s 46/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about EDIT

Is Editas Medicine, Inc. (EDIT) a buy?

As of 2026-11-20, MELANY rated Editas Medicine, Inc. Promising with a composite score of 46/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does EDIT rank against similar companies?

As of November 20, 2026, Editas Medicine, Inc. ranks 8th of the 10 companies with a MELANY rating page in its SEC industry group (Biological Products, (No Diagnostic Substances)), where the average score is 53. Among the other names in the group, the highest scores belong to AMGN (62) and BIIB (60).

Should I buy Editas Medicine, Inc. stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Editas Medicine, Inc. (EDIT) Promising with a composite of 46/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the EDIT stock price forecast?

MELANY does not publish price targets or forecasts for EDIT. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 46/100 across eight factors for Editas Medicine, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for EDIT as of 2026-11-20: its analyst sentiment factor is 89/100 (Analyst targets 272% upside), and its price momentum factor is 10/100.

Is EDIT stock overvalued or undervalued?

MELANY's valuation factor currently reads 63/100 for Editas Medicine, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives EDIT's read.

What price should I buy EDIT at?

Rather than chasing the current price, MELANY computes a smart entry zone for EDIT: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying EDIT stock?

The top risks MELANY currently flags for Editas Medicine, Inc.: Operating margin -152%, cash-burn business, dependent on capital markets; Negative free cash flow, company consuming cash, not generating it; Short interest 25% of float, high volatility risk on news; Weak price momentum, trend not yet confirmed, may need more time to set up; High beta 2.1, amplifies market drawdowns 1.8x+ in selloffs. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Editas Medicine, Inc. a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 26/100 for Editas Medicine, Inc., and earnings track record, at 100/100. The 46/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will EDIT stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 10/100 for EDIT right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this EDIT rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores EDIT as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, EDIT included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.